Dr. Sclafani and Dr. Siskin on CCSVI Coalition SAB
Posted: Thu Nov 03, 2011 10:36 am
http://www.newswire.ca/en/story/870989/ ... ent-and-ms
Today the CCSVI Coalition announced its Scientific Advisory Board (SAB). The advisory group of diagnostic, treatment and pathology experts has extraordinary insight into CCSVI and MS and a wealth of practical experience in assessing and treating people with CCSVI. They have been assembled to be an expert resource for researchers and government on these issues and to facilitate a balanced and open dialogue regarding CCSVI and MS.
The CCSVI Coalition Scientific Advisory Board of experts includes:
• Dr. Bill Code, Duncan, BC, Can - MD and chronic pain specialist
• Dr. Mark Godley, Vancouver, BC, Can - anaesthesiology, cross discipline medical interventions
• Dr. Sandy McDonald, Barrie, ON, Can. - Cardiovascular & thoracic surgeon; Dopler sonography protocols
• Dr. Mark Haacke, Detroit Mich, USA - Phd, MR research & MRV protocols
• Dr. David Hubbard, San Diego Calif., USA - MD, neurologist & sponsor CCSVI multi-centre registry
• Dr. Salvatore Sclafani, Brooklyn, NY USA, Interventional Radiologist; Intravascular Ultra Sound (IVUS)
• Dr. Gary Siskin, Albany, NY, USA - Interventional Radiologist; CCSVI safety co-author
Taken together, Drs. Sclafani and Siskin have performed over 400 CCSVI treatments as practicing Interventional Radiologists.
The Scientific Advisory Board is Chaired by Dr. Michael E. Shannon, an acknowledged expert in designing and running large clinical trials. He is well known to government and medical experts in Canada through his past positions as Deputy Surgeon General, Director General of The Laboratory Centers for Disease Control and Senior Medical Advisor to the Canadian Public Health Agency.
"We are delighted that there are to be CCSVI trials in Canada. This is an exciting new area of study that has aroused many hopes and much controversy," said Dr. Michael Shannon. "We wish to contribute constructively to the process of preparing an RFP for the Phase I/II trial for CCSVI and MS by offering our expert help to the Canadian Institutes of Health Research and Health Canada to make the trials the best they possibly can be."